Form 4: Zimmer Biomet Director Robert Hagemann Acquires Stock

Director Robert Hagemann acquired 308.711 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan.

Summary

• Director Robert Hagemann acquired 308.711 phantom stock units on March 31, 2026.
• The acquisition was made under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• The units are valued at a 1-for-1 conversion ratio to common stock.
• Following this transaction, the director holds a total of 31,982.841 phantom stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or strategy.

Positives

• Demonstrates continued alignment of director interests with company performance through deferred compensation participation.

Negatives

• None identified.

Risks

• The value of phantom stock units is tied to the performance of the company's common stock, exposing the director to market volatility.

Future Outlook

The units are to be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the director's service ceases.

Management Comments

• The transaction reflects standard participation in the company's Deferred Compensation Plan for Non-Employee Directors.

Industry Context

StockSavvy.ai notes that director participation in deferred compensation plans is a standard corporate governance practice in the medical device industry, intended to align long-term director incentives with shareholder value.

Comparison to Industry Standards

• The use of phantom stock units for director compensation is consistent with practices at peer companies like Stryker and Medtronic.
• The 1-for-1 conversion ratio is standard for deferred compensation plans in the S&P 500.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation-related transaction.

Next Steps

• No further action required; this is a routine disclosure of director holdings.

Key Dates

Keywords

Zimmer Biomet, ZBH, Form 4, Director Compensation, Insider Transaction, Phantom Stock